US OptionsDetailed Quotes
PFE250110P28000
- 1.20
- 0.000.00%
15min DelayTrading Jan 10 16:00 ET
0.00High0.00Low
0.00Open1.20Pre Close0 Volume0 Open Interest28.00Strike Price0.00Turnover0.00%IV-2.27%PremiumJan 10, 2025Expiry Date1.80Intrinsic Value100Multiplier-12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma21.84Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Pfizer Stock Discussion
Tomorrow is the XD.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
Alright, im dreaming
Pfizer has completed a secondary offering of 700 million Haleon ordinary shares at 357 pence (approximately $4.36) per share on January 17, 2025. The sale was executed through a block trade agreement with multiple financial institutions including J.P. Morgan Securities, Morgan Stanley, HSBC, and others.
Following the transaction, Pfizer now holds 661,709,764 Haleon ordinary shares, representing approximately 7.3% of Haleon's outstanding shares. This includes 197,228,952 restric...
Full year earnings release on 04 Feb 2025. Waiting for good results
Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering.
In an SEC filing, Ascentage (AAPG) said it plans to offer 7.3M American Depositary Shares, representing 29.3M ordinary shares. While the company didn't disclose a price range, it indicated in its filing fee schedule it was looking to raise around $170M.
The company hopes to list its shares on Nasdaq under the symbol A...
No comment yet